⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MNKD News
Mannkind Corporation
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
globenewswire.com
MNKD
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
prnewswire.com
ALT
ARWR
MNKD
LCTX
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
prnewswire.com
ARDX
FATE
MNKD
VRTX
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
globenewswire.com
MNKD
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
globenewswire.com
MNKD
VRTX
FATE
ARDX
Molecular Switch Targeting Therapies Market Research Report 2026: Opportunities in Targeted Drug Delivery Systems and Therapies in Oncology, Autoimmune, Inflammatory, and Neurological Disorders
globenewswire.com
MRK
BMY
AZN
PFE
NVS
LLY
GILD
JNJ
REGN
ABBV
NVO
SNY
VRTX
AMGN
BIIB
INCY
EXEL
SRPT
CRSP
EDIT
NTLA
ALNY
MRNA
BNTX
COHR
IMUX
INSM
CYTK
KODK
LULU
NVDA
GOOG
MSFT
IBM
AMAT
ILMN
ALKS
ACAD
MNKD
TEVA
BHC
XBI
IBB
XLF
XLK
XLV
JAZZ
ACGL
MannKind Provides Business Updates and 2026 Growth Drivers
globenewswire.com
MNKD
MannKind Shares FUROSCIX® Business Updates
globenewswire.com
MNKD
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
globenewswire.com
MNKD
MannKind to Present at the Jefferies Global Healthcare Conference
globenewswire.com
MNKD